Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Duel Administration of Both Anavex Drugs

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
falconer66a Member Profile
 
Followed By 73
Posts 1,391
Boards Moderated 0
Alias Born 01/29/04
160x600 placeholder
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) GlobeNewswire Inc. - 2/24/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
falconer66a   Saturday, 04/13/19 12:47:06 PM
Re: McMagyar post# 189460
Post # of 238287 
Duel Administration of Both Anavex Drugs
Quote:
What about a3-71 and a2-73 as a combination drug?


Well, that combination would be, for me, a prime therapeutic goal; something to be focused on. First, of course, in transgenic murines (lab rats, with inserted genes of human central nervous system diseases; then, as quickly as possible, in human trials.

Why? The safety and multiple efficacies of Anavex 2-73 are so clearly established in transgenic murines that the three consequent human trials are proceeding, Rett syndrome (a 15-n, short human trial), Parkinson’s disease, and the final full-scale Altzheimer’s clinical trial involving 450 Australians.

But, then, what about Anavex 3-71? Simply, it either parallels or exceeds the positive therapeutic outcomes of Anavex 2-73 for various, multiple CNS diseases (and very likely others, where mitochondrial dysfunction is causative or complicating). A bit of the unique therapeutic traits of Anavex 3-71 are touched upon here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147390529

But do one’s own diligence on the subject. In a browser read what comes up with this search:
anavex 3-71 advantages

Combining both of these powerful Anavex sigma-1 receptor agonists is likely to yield, at least, the favorable outcomes of one of the two. In combination there may well be a therapeutic synergy, where 1 + 1 = >2.

It’s not something difficult to assess with murines. I’m certain that Anavex Life Sciences Corp has data on such trials; but holding them for propitious revelation sometime in the future — perhaps after positive, confirming results emerge from any of the three human Anavex 2-73 trials underway.

Might all of this be clinical gamesmanship by Dr. Missling, setting in place some really spectacular murine results to be released after the three clinical trials establish Anavex 2-73 safety and efficacies in real humans? The big headlines from those, later this year, will be in the nature of, “New Anavex Drug Demonstrates Safety, Efficacy Against Three CNS Diseases.”

That will be really great. But what will be the results of a consequent media release by Anavex with a paragraph lead such as this:

“Anavex Life Sciences Corp is extremely pleased with the very positive therapeutic results Anavex 2-73 has proven in three clinical trials. We will now move forward with new clinical trials for a number of diseases caused by or involved with mitochondrial and autophagy dysfunctions. We have extensive murine data showing that duel administration of both Anavex 2-73 and Anavex 3-71 yields remarkable preventions and resolutions of a wide variety of human diseases with those involvements. We see this duel drug administration taking Anavex Life Sciences Corp to an even greater role as a major pharmaceutical corporation, treating or preventing an ever-wider diversity of diseases and conditions — as demonstrated in our extensive studies with transgenic murines.”


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist